Sumitomo Mitsui Trust Holdings Inc. Has $153.84 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,609,866 shares of the medical research company’s stock after buying an additional 6,563 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned 0.27% of Edwards Lifesciences worth $153,839,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of EW. Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock valued at $3,992,709,000 after buying an additional 729,984 shares during the last quarter. Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 20.1% in the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after purchasing an additional 3,048,274 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after buying an additional 393,109 shares during the last quarter. Norges Bank bought a new stake in Edwards Lifesciences during the fourth quarter worth $648,540,000. Finally, Sands Capital Management LLC grew its stake in shares of Edwards Lifesciences by 34.6% in the 4th quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock worth $465,407,000 after acquiring an additional 1,567,526 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, CEO Bernard J. Zovighian bought 580 shares of the stock in a transaction dated Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Bernard J. Zovighian acquired 580 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The shares were bought at an average cost of $85.74 per share, with a total value of $49,729.20. Following the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 119,849 shares of company stock worth $10,579,038. 1.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on EW. Wells Fargo & Company increased their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Piper Sandler lifted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday, April 26th. Evercore ISI upped their price objective on Edwards Lifesciences from $89.00 to $91.00 and gave the company an “in-line” rating in a research note on Tuesday. Finally, Mizuho raised their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $95.18.

Edwards Lifesciences Trading Up 0.8 %

NYSE EW traded up $0.77 on Wednesday, hitting $92.00. The company’s stock had a trading volume of 339,502 shares, compared to its average volume of 3,434,557. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The firm has a market cap of $55.44 billion, a P/E ratio of 39.58, a PEG ratio of 3.38 and a beta of 1.11. The company’s 50-day simple moving average is $87.99 and its 200 day simple moving average is $85.56.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.